Mouse model for efficacy testing of antituberculosis agents via intrapulmonary delivery

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 7, 2012, Pages 3957-3959

  Gonzalez Juarrero, Mercedes ^a   Woolhiser, Lisa K ^a   Brooks, Elizabeth ^a   DeGroote, Mary Ann ^a   Lenaerts, Anne J ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CAPREOMYCIN; ISONIAZID; TUBERCULOSTATIC AGENT;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL LOAD; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEMALE; INTRAPULMONARY DRUG ADMINISTRATION; LUNG TUBERCULOSIS; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SPLEEN; TREATMENT DURATION;

ADMINISTRATION, INHALATION; ANIMALS; ANTITUBERCULAR AGENTS; FEMALE; ISONIAZID; LUNG; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, PULMONARY;

EID: 84862576659     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00464-12     Document Type: Article

References (25)

1. Caminero JA, Sotgiu G, Zumla A, Migliori GB. 2010. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect. Dis. 10:621-629.
2. De Groote MA, et al. 2011. Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 55:1237-1247.
3. De Groote MA, et al. 2012. Importance of confirming data on the in vivo efficacy of novel antibacterial drug regimens against various strains of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 56:731-738.
4. Hickey AJ, Misra A, Robertson BD. 2011. Optimisation of inhaled tuberculosis therapies and implications for host-pathogen interactions. Tuberculosis (Edinb.) 91:64.
5. Klemens SP, DeStefano MS, Cynamon MH. 1993. Therapy of multidrug-resistant tuberculosis: lessons from studies with mice. Antimicrob. Agents Chemother. 37:2344-2347.
6. Le Conte P, et al. 1994. Pharmacokinetics, toxicity, and efficacy of liposomal capreomycin in disseminated Mycobacterium avium beige mouse model. Antimicrob. Agents Chemother. 38:2695-2701.
7. Lounis N, Ji B, Truffot-Pernot C, Grosset J. 1997. Comparative activities of amikacin against Mycobacterium avium complex in nude and beige mice. Antimicrob. Agents Chemother. 41:1168-1169.
8. Lu D, et al. 2010. Pulmonary immunization using antigen 85-B polymeric microparticles to boost tuberculosis immunity. AAPS J. 12:338-347.
9. Lu D, et al. 2007. Poly (lactide-co-glycolide) microspheres in respirable sizes enhance an in vitro T cell response to recombinant Mycobacterium tuberculosis antigen 85B. Pharm. Res. 24:1834-1843.
10. Misra A, et al. 2011. Inhaled drug therapy for treatment of tuberculosis. Tuberculosis (Edinb.) 91:71-81.
11. Muttil P, et al. 2007. Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur. J. Pharm. Sci. 32:140-150.
12. Muttil P, Wang C, Hickey AJ. 2009. Inhaled drug delivery for tuberculosis therapy. Pharm. Res. 26:2401-2416.
13. O'Hara P, Hickey AJ. 2000. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization. Pharm. Res. 17:955-961.
14. Paraf J, Zivy P, Fournier E. 1955. Aerosol therapy and cationic tensioactive drugs in pulmonary tuberculosis. Sem Hop. 31:4163-4164. (In French.)
15. Rosas-Taraco AG, et al. 2009. Intrapulmonary delivery of XCL1-targeting small interfering RNA in mice chronically infected with Mycobacterium tuberculosis. Am. J. Respir. Cell Mol. Biol. 41:136-145.
16. Rosas-Taraco AG, et al. 2011. Local pulmonary immunotherapy with siRNA targeting TGFbeta1 enhances antimicrobial capacity in Mycobacterium tuberculosis infected mice. Tuberculosis (Edinb.) 91:98-106.
17. Rosenthal IM, Zhang M, Almeida D, Grosset JH, Nuermberger EL. 2008. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? Am. J. Respir. Crit. Care Med. 178:989-993.
18. Rosenthal IM, et al. 2007. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med. 4:e344. doi: 10.1371/journal.pmed.0040344.
19. Sanders WE, Jr, Hartwig C, Schneider N, Cacciatore R, Valdez H. 1982. Activity of amikacin against Mycobacteria in vitro and in murine tuberculosis. Tubercle 63:201-208.
20. Sethuraman VV, Hickey AJ. 2002. Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug. AAPS PharmSciTech. 3:E28.
21. Sharma A, Sharma S, Khuller GK. 2004. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J. Antimicrob. Chemother. 54:761-766.
22. Shi S, Hickey AJ. 2010. PLGA microparticles in respirable sizes enhance an in vitro T cell response to recombinant Mycobacterium tuberculosis antigen TB10.4-Ag85B. Pharm. Res. 27:350-360.
23. Suarez S, et al. 2001. Airways delivery of rifampicin microparticles for the treatment of tuberculosis. J. Antimicrob. Chemother. 48:431-434.
24. Suarez S, et al. 2001. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model. Pharm. Res. 18:1315-1319.
25. Wang C, Hickey AJ. 2010. Isoxyl aerosols for tuberculosis treatment: preparation and characterization of particles. AAPS PharmSciTech. 11: 538-549.